

- Azithromycin (*Cont.*):  
 for pneumonia, 953  
 in pregnancy and lactation, 246e-4t, 937t  
 prophylactic  
   for *Bartonella* infection in HIV infection, 1252t  
   for MAC infection in HIV infection, 1251t  
   for meningitis, 889  
 for reactive arthritis, 2175  
 resistance to  
   mechanisms of, 931t  
   in nontuberculous mycobacteria, 205e-8  
   prevalence of, 940t  
   prevention of, 226  
   in *S. pyogenes*, 233  
   in *T. pallidum*, 1138  
 for scrub typhus, 1159  
 for *Shigella* infections, 1058t  
 for streptococcal pharyngitis, 966  
 for syphilis, 1138  
 for trachoma, 1172  
 for travelers' diarrhea, 797, 857t  
 for urethritis, 871, 872t
- Azole antifungals, 1330–1331. *See also specific drugs*
- Azotemia, **290**. *See also* Acute kidney injury (AKI)  
 approach to the patient, 290f, 291  
 glomerular filtration rate and, 290–291  
 in malabsorption syndrome, 1945  
 with parenteral nutrition, 98e-7t  
 in urinary tract obstruction, 1872
- AZT. *See* Zidovudine (AZT)
- Aztreonam  
 indications for, 940t, 941–942  
 for infections in cancer patient, 491  
 resistance to, 940t  
 for sepsis/septic shock, 1757t
- Azul. *See* Pinta
- Azurophil granules, 415
- B**
- BAALC overexpression, 680, 680t
- Babesia* spp.  
 coinfections of, 781  
 geographic distribution of, 245e-4t  
 laboratory identification of, 250e-1, 250e-4f, 1386f  
 life-cycle hosts of, 245e-4t  
 transmission of, 245e-4t, 1384
- Babesia* spp. infections, **1384**  
 in cancer patient, 484, 484t  
 clinical features of, 1384–1385  
 co-infection with Lyme disease, 1152, 1385  
 complications of, 781  
 diagnosis of, 150e-8, 245e-4t, 245e-6t, 250e-4f, 1385–1386, 1386f  
 epidemiology of, 245e-4t, 1384  
 etiology of, 780t, 781  
 global considerations in, 1384, 1385f  
 in immunocompromised patient, 1387  
 pathogenesis of, 1385  
 prevention of, 1387  
 in splenectomized patient, 413  
 transmission of, 138e-6, 1384  
 treatment of, 780t, 1386–1387, 1386t
- Babes nodules, 1301
- Babinski sign, 154, 154t, 1772, 1775, 2539
- Bacillary angiomatosis, **1082**  
 clinical features of, 133t, 1082, 1083f  
 diagnosis of, 1083  
 epidemiology of, 1082  
 etiology of, 1082  
 in HIV infection, 365, 1082, 1083f, 1268  
 pathology of, 1082–1083  
 prevention of, 1083  
 skin manifestations of, 133t, 364t, 365  
 treatment of, 832t, 1081t, 1083
- Bacillary peliosis, 1081t, 1082–1083
- Bacille Calmette-Guérin (BCG) vaccine, 1120, 1128
- Bacillus anthracis*, 261e-2. *See also* Anthrax
- Bacillus Calmette-Guérin (BCG), for bladder cancer, 576
- Bacillus cereus* infections  
 clinical features of, 258, 266t, 853  
 food-borne, 856, 856t  
 in transplant recipient, 919
- Bacitracin, 930, 931t
- Back pain, **111**  
 in ankylosing spondylitis, 2170, 2172  
 in cancer patient, 117, 118, 530, 588, 1790–1792, 1791f  
 causes of, **114**, 115t  
   arthritis, 117  
   autoimmune inflammatory disease, 118  
   congenital anomalies, 118  
   degenerative, 115–116, 116f  
   infections/inflammation, 117, 784, 839  
   lumbar disk disease, 113f, 114–115, 115f  
   metabolic, 117–118, 426e-2  
   metastatic disease, 2653  
   postural, 118  
   psychiatric, 118  
   spondylolisthesis, 117  
   spondylosis, 117  
   traumatic, 117  
 chronic, 119–120  
 costs of, 111  
 diagnosis of, 113–114, 440e-10  
 in hemolysis, 393  
 idiopathic, 118  
 local, 111  
 patient education in, 119  
 physical examination in, 112–113, 114t  
 radicular, 112  
 referred from other locations, 111, 118  
 risk factors for serious cause, 113t  
 of spine origin, 111  
 treatment of, **118**  
   acute pain without radiculopathy, 119  
   chronic pain without radiculopathy, 119–120  
   clinical care systems view, 118–119  
   nerve root and epidural spinal injections, 440e-10  
   pain with radiculopathy, 120–121  
 types of, 111–112
- Baclofen  
 for dystonia, 2621  
 for GERD, 263  
 overdose/poisoning with, 473e-10t  
 for pain, 61  
 for spasticity, 2660, 2672  
 for stiff-person syndrome, 618  
 for tardive dyskinesia, 2624  
 for trigeminal neuralgia, 2646
- Bacteremia  
*A. baumannii*, 1037  
 anaerobic bacterial, 1100  
 chronic *B. quintana*, 1081t, 1082  
 clostridial, 992  
 definition of, 1751t  
*E. coli*, 1029  
*Enterobacter*, 1034  
*Klebsiella*, 1033  
*L. monocytogenes*, 983  
 nontyphoidal *Salmonella*, 1054, 1054t  
*P. aeruginosa*, 1044, 1045t  
*Proteus*, 1033  
 streptococcal, 968
- Bacteria  
 adherence of, 145e-2–3, 145e-2t, 852  
 antibiotic resistance in. *See* Antibacterial drugs, resistance to  
 avoidance of host defenses by, 145e-4–7, 145e-6f  
 colonic, 265  
 culture-independent studies of, 86e-2–4, 86e-3f  
 genome sequences of, 768, 770f, 776  
 gram-negative. *See* Gram-negative bacteria  
 gram-positive. *See* Gram-positive bacteria  
 growth after entry, 145e-4  
 host receptors of, 145e-3  
 in human microbiome, 86e-2–3  
 laboratory identification of, **150e-1**  
   blood culture for, 150e-3  
   gas-liquid chromatography for, 150e-3  
   genomics in, 769t, 770–772  
   limitations of, 770  
   macroscopic antigen detection for, 150e-2  
   microscopy for, 150e-1  
   multiplex sequencing in, 86e-2–4, 86e-3f  
   specimen-processing algorithm for, 150e-6f  
   staining in, 150e-1–2  
   susceptibility testing, 150e-8  
 tissue invasion by, 145e-7–8, 145e-9–10  
 toxin production by, 145e-9, 852–853  
 viruses infecting, 86e-4
- Bacterial endocarditis. *See* Infective endocarditis
- Bacterial infections. *See also specific bacteria and bacterial types*  
 anaerobic, mixed. *See* Anaerobic bacterial infections, mixed  
 as cause of fever of unknown origin, 137t. *See also* Acute febrile illness  
 in pregnancy, 49–50  
 transfusion-transmitted, 138e-6  
 in transplant recipient  
   after HSCT, 919–920, 920t  
   after kidney transplantation, 924–926, 924t, 1829–1831, 1830t  
   after liver transplantation, 924t, 927–928, 1341f, 2072–2073
- Bacterial meningitis. *See* Meningitis, bacterial
- Bacterial overgrowth syndromes, **1944**  
 cobalamin absorption in, 350e-1, 350e-1t  
 diagnosis of, 271, 1941t, 1944  
 diarrhea in, 269, 1944  
 etiology of, 269, 1944  
 pathogenesis of, 1944  
 small-intestinal, 263, 1940t  
 steatorrhea in, 1944  
 in systemic sclerosis, 2162, 2164  
 treatment of, 1944
- Bacterial pods, 145e-5
- Bacterial vaginosis  
 clinical features of, 873t  
 complications of, 873  
 diagnosis of, 873t, 874, 874f, 875f  
 etiology of, 873t, 874, 1099  
 HIV transmission and, 1221  
 treatment of, 873t, 875
- Bactericidal drugs, 930. *See also* Antibacterial drugs
- Bactericidal/permeability-increasing protein (Bpi), 372e-24t
- Bacteriostatic drugs, 930. *See also* Antibacterial drugs
- Bacteriuria. *See* Urinary tract infections (UTIs)
- Bacteroides* spp., 1094–1095
- Bacteroides fragilis*  
 antibiotic resistance in, 1101  
 gut immune functions of, 86e-8  
 in normal human microbiota, 1094–1096, 1095t  
 virulence factors of, 849
- Bacteroides fragilis* infections. *See also* Anaerobic bacterial infections, mixed  
 bacteremia, 1100  
 female genital tract, 849, 1099  
 head and neck, 1097  
 intraabdominal, 1099  
 intraperitoneal abscess, 849  
 liver abscess, 850  
 pathogenesis of, 1096  
 peritonitis, 847  
 treatment of, 940t, 1101
- “Bad news” situation, communication in, 57–58, 57t
- BAEPs (brainstem auditory evoked potentials), 223, 442e-3
- Bagassosis, 1681t
- Baker's (popliteal) cyst, 1632, 2222
- Balamuthia* spp., 245e-4t, 1367, 1368
- Balamuthia* spp. infections  
 in chronic meningitis, 908t  
 clinical features of, 1368  
 diagnosis of, 245e-4t, 245e-6t, 1368  
 encephalitis, 896, 1368, 1368f  
 epidemiology of, 245e-4t  
 treatment of, 1368